Comparing Antifungal Treatments for Neutropenic Patients
Author Information
Author(s): Amy Riedel, Lan Choe, John Inciardi, Courtney Yuen, Thomas Martin, Joseph Guglielmo
Primary Institution: University of California San Francisco
Hypothesis
Is an azole-based antifungal regimen more effective and safer than conventional amphotericin B in neutropenic hematology/oncology patients?
Conclusion
An azole-based regimen is associated with increased costs but reduced nephrotoxicity compared to amphotericin B, although it may increase the risk of severe hepatic toxicity with voriconazole.
Supporting Evidence
- The incidence of breakthrough fungal infections was similar between the two regimens.
- Azole treatment was associated with significantly lower rates of mild/moderate and severe renal dysfunction.
- Voriconazole was linked to a higher rate of severe hepatic toxicity compared to amphotericin B.
Takeaway
This study looked at two types of antifungal medicines for patients with low white blood cell counts. It found that one type is safer for the kidneys but can be more expensive and might hurt the liver more.
Methodology
This was a retrospective, observational cohort study comparing outcomes of patients receiving either amphotericin B or azole-based antifungal prophylaxis.
Potential Biases
The influence of confounding factors is a concern due to the observational nature of the study.
Limitations
The study's retrospective design may introduce confounding factors, and the analysis of patients receiving multiple courses of antifungals presents challenges.
Participant Demographics
Adult neutropenic hematology/oncology patients, with a mean age of approximately 50 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 0.42–0.95
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website